# Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

Source: https://onco.cc/trials/nct02650401/  
OnCo record `nct02650401` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Entrectinib in brain and spinal cord tumours, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options is a phase 1/2 interventional study registered as NCT02650401 by Hoffmann-La Roche, with 69 participants enrolled, started 2016-05-03 and due to reach its primary completion in 2026-06-30. Interventions recorded: Entrectinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02650401
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
- Sponsor: Hoffmann-La Roche
- Enrolled: 69

## Sources

- ClinicalTrials.gov NCT02650401: https://clinicaltrials.gov/study/NCT02650401

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- drugs: [Entrectinib](https://onco.cc/drugs/entrectinib/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct02650401.json